MedPath

Comparative Bioavailability Study of Morphine Sulfate Immediate Release and Controlled Release

Not Applicable
Completed
Conditions
Pain
Registration Number
NCT00994383
Lead Sponsor
Roxane Laboratories
Brief Summary

Characterize the steady-state pharmacokinetics of morphine after oral administration of Roxane Laboratories' morphine sulfate immediate release tablets and oral solution and to compare their pharmacokinetics to that of AVINZA.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
Exclusion Criteria
  • Positive test for HIV, Hepatitis B, or Hepatitis C.
  • Treatment with known enzyme altering drugs.
  • History of allergic or adverse response to morphine sulfate or any comparable or similar product.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
bioequivalence determined by statistical comparison Cmax15 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CEDRA Clinical Research

🇺🇸

Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath